Summary
Boston Scientific Corporation (BSX) has filed an 8-K report on June 11, 2018, addressing market speculation regarding a potential acquisition. The company acknowledges awareness of reports suggesting that Stryker Corporation has approached BSX about a possible takeover. However, in line with its standard policy, Boston Scientific has stated that it does not comment on market rumors or speculation. This disclosure is made under Regulation FD and is intended to inform investors and the market about the company's official stance on these unconfirmed reports.
Key Highlights
- 1Boston Scientific acknowledges awareness of market speculation concerning a potential acquisition approach from Stryker Corporation.
- 2The company officially states that it does not comment on market rumors or speculation.
- 3The disclosure is made under Regulation FD to ensure fair and broad dissemination of information.
- 4The filing does not confirm or deny the validity of the acquisition rumors.
- 5Investors should note that this information is not deemed 'filed' for purposes of Section 18 of the Exchange Act, meaning it does not carry the same liability as other filed information.